The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

Have you experienced pain or tingling in your hands or feet? Those are signs of possible neuropathy, “a general term for ...

Arialief is a comprehensive nerve health supplement that specifically targets sciatic nerve pain and claims to provide ...

While cannabinoids offer a potential alternative for refractory chronic pain, optimal use requires personalized dosing and ...

Cannabidiol (CBD) holds promise as a treatment for many health concerns, including inflammation. For all the known benefits CBD offers, it’s unclear how well it can relieve nerve pain.

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

In 2004, a research group at Peking University First Hospital discovered a mutation in the gene coding for a sodium-channel ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...